Adherium Smartinhaler

Big pharma buys into smart inhalers

Australian digital health group Adherium will start selling smart inhalers to pharmaceutical makers in a move that has been backed by pharma giant AstraZeneca

Adherium plans to sell the trademarked Smartinhaler platform directly to pharmaceutical companies, who then provide the device and supporting applications to end users via their own distribution channels.

The company already currently supplies its Smartinhaler platform to disease management organisations and organisations conducting clinical trials.

Clinical studies have shown that the Smartinhaler increases medication adherence by up to 59% in adults and 180% in children. In addition, use of Smartinhaler resulted in a 60% reduction in severe attacks in adults.

The Smartinhaler recently raised sufficient funds from investors to allow Adherium to manufacture at commercial quantities.

In addition the firm has signed long term supply and development agreement with global biopharmaceutical company AstraZeneca.

Adherium Group Chief Executive Officer Garth Sutherland said, “I am thrilled with the overwhelming investor support ranging from international institutional investors through to small retail investors. The Adherium team is committed to providing market-leading digital health solutions that have a real and meaningful impact for people with chronic disease. We believe our proven ability to innovate and deliver will ensure we generate ongoing value for our shareholders.”



Dave is the Editor of Med-Tech Innovation magazine. He also holds the position of Deputy Group Editor for the Rapid Life Sciences portfolio. You can reach Dave via his email - david.g@rapidnews.com


'Big pharma buys into smart inhalers' has no comments

Be the first to comment this post!

Would you like to share your thoughts?

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

© 2019 Rapid Life Sciences Ltd, a Rapid News Communications Group Company. All Rights Reserved.

Privacy policy

Terms and conditions